Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks (Q33332394)

From Wikidata
Jump to navigation Jump to search
scientific article
edit
Language Label Description Also known as
English
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks
scientific article

    Statements

    Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks (English)

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit